• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

常染色体显性多囊肾病的家族内变异性

Intrafamilial Variability of ADPKD.

作者信息

Lanktree Matthew B, Guiard Elsa, Li Weili, Akbari Pedram, Haghighi Amirreza, Iliuta Ioan-Andrei, Shi Belili, Chen Chen, He Ning, Song Xuewen, Margetts Peter J, Ingram Alistair J, Khalili Korosh, Paterson Andrew D, Pei York

机构信息

Division of Nephrology, University Health Network, Toronto, Ontario, Canada.

Division of Nephrology, University of Toronto, Toronto, Ontario, Canada.

出版信息

Kidney Int Rep. 2019 May 7;4(7):995-1003. doi: 10.1016/j.ekir.2019.04.018. eCollection 2019 Jul.

DOI:10.1016/j.ekir.2019.04.018
PMID:31317121
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6611955/
Abstract

INTRODUCTION

Discordance in kidney disease severity between affected relatives is a recognized feature of autosomal dominant polycystic kidney disease (ADPKD). Here, we report a systematic study of a large cohort of families to define the prevalence and clinical features of intrafamilial discordance in ADPKD.

METHODS

The extended Toronto Genetic Epidemiology Study of Polycystic Kidney Disease (eTGESP) cohort includes 1390 patients from 612 unrelated families with ADPKD ascertained in a regional polycystic kidney disease center. All probands underwent comprehensive and mutation screening. Total kidney volume by magnetic resonance imaging (MRI) was available in 500 study patients.

RESULTS

Based on (i) rate of estimated glomerular filtration rate (eGFR) decline, (ii) age at onset of end-stage renal disease (ESRD), and (iii) Mayo Clinic Imaging Classification (MCIC), 20% of patients were classified as having mild disease, and 33% as having severe disease. Intrafamilial ADPKD discordance with at least 1 mild and 1 severe case was observed in 43 of 371 (12%) families, at a similar frequency regardless of the responsible gene (no mutation detected) or mutation type (protein-truncating versus nontruncating). Intrafamilial discordance was more common in larger families and was present in 30% of families with more than 5 affected members. The heritability of age at onset of ESRD was similar between different mutation types.

CONCLUSION

Extreme kidney disease discordance is present in at least 12% of families with ADPKD, regardless of the underlying mutated gene or mutation class. Delineating genetic and environmental modifiers underlying the observed intrafamilial ADPKD variability will provide novel insights into the mechanisms of progression in ADPKD.

摘要

引言

患病亲属间肾病严重程度的不一致是常染色体显性多囊肾病(ADPKD)的一个公认特征。在此,我们报告了一项对大量家系队列的系统性研究,以确定ADPKD家族内不一致性的患病率及临床特征。

方法

多囊肾病多伦多遗传流行病学扩展研究(eTGESP)队列包括来自一个地区多囊肾病中心确诊的612个无关ADPKD家系的1390名患者。所有先证者均接受了全面的突变筛查。500名研究患者可获得通过磁共振成像(MRI)测量的总肾体积。

结果

基于(i)估计肾小球滤过率(eGFR)下降率、(ii)终末期肾病(ESRD)发病年龄以及(iii)梅奥诊所影像分类(MCIC),20%的患者被分类为轻度疾病,33%为重度疾病。在371个家系中的43个(12%)家系中观察到家族内ADPKD不一致,即至少有1例轻度和1例重度病例,无论致病基因(未检测到突变)或突变类型(截短蛋白型与非截短蛋白型)如何,其发生频率相似。家族内不一致在较大的家系中更为常见,在有超过5名患病成员的家系中占30%。不同突变类型之间ESRD发病年龄的遗传度相似。

结论

无论潜在的突变基因或突变类别如何,至少12%的ADPKD家系存在极端的肾病不一致情况。描绘观察到的家族内ADPKD变异性背后的遗传和环境修饰因素将为ADPKD的进展机制提供新的见解。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/629e/6611955/24f103ddc75f/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/629e/6611955/458d96f2e250/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/629e/6611955/9b82f96cf465/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/629e/6611955/120f37381e4e/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/629e/6611955/8e771c579e9a/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/629e/6611955/1e648fc868df/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/629e/6611955/24f103ddc75f/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/629e/6611955/458d96f2e250/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/629e/6611955/9b82f96cf465/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/629e/6611955/120f37381e4e/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/629e/6611955/8e771c579e9a/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/629e/6611955/1e648fc868df/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/629e/6611955/24f103ddc75f/gr5.jpg

相似文献

1
Intrafamilial Variability of ADPKD.常染色体显性多囊肾病的家族内变异性
Kidney Int Rep. 2019 May 7;4(7):995-1003. doi: 10.1016/j.ekir.2019.04.018. eCollection 2019 Jul.
2
Patients with Protein-Truncating Mutations and Mild ADPKD.携带蛋白截断突变的常染色体显性多囊肾病患者。
Clin J Am Soc Nephrol. 2021 Mar 8;16(3):374-383. doi: 10.2215/CJN.11100720. Epub 2021 Feb 18.
3
Familial Variability of Disease Severity in Adult Patients With ADPKD.成人常染色体显性多囊肾病患者疾病严重程度的家族变异性
Kidney Int Rep. 2023 Dec 12;9(3):649-660. doi: 10.1016/j.ekir.2023.12.002. eCollection 2024 Mar.
4
Refining Genotype-Phenotype Correlation in Autosomal Dominant Polycystic Kidney Disease.完善常染色体显性多囊肾病的基因型 - 表型相关性
J Am Soc Nephrol. 2016 Jun;27(6):1861-8. doi: 10.1681/ASN.2015060648. Epub 2015 Oct 9.
5
Predicted Mutation Strength of Nontruncating PKD1 Mutations Aids Genotype-Phenotype Correlations in Autosomal Dominant Polycystic Kidney Disease.非截短型PKD1突变的预测突变强度有助于常染色体显性多囊肾病的基因型-表型关联研究
J Am Soc Nephrol. 2016 Sep;27(9):2872-84. doi: 10.1681/ASN.2015050583. Epub 2016 Jan 28.
6
PKD2-Related Autosomal Dominant Polycystic Kidney Disease: Prevalence, Clinical Presentation, Mutation Spectrum, and Prognosis.与PKD2相关的常染色体显性多囊肾病:患病率、临床表现、突变谱及预后
Am J Kidney Dis. 2017 Oct;70(4):476-485. doi: 10.1053/j.ajkd.2017.01.046. Epub 2017 Mar 27.
7
A novel PKD1 variant demonstrates a disease-modifying role in trans with a truncating PKD1 mutation in patients with autosomal dominant polycystic kidney disease.一种新的PKD1变异体在常染色体显性遗传性多囊肾病患者中与截短型PKD1突变呈反式作用,表现出疾病修饰作用。
BMC Nephrol. 2015 Mar 1;16:26. doi: 10.1186/s12882-015-0015-7.
8
Genotype-renal function correlation in type 2 autosomal dominant polycystic kidney disease.2型常染色体显性遗传性多囊肾病的基因型与肾功能的相关性
J Am Soc Nephrol. 2003 May;14(5):1164-74. doi: 10.1097/01.asn.0000061774.90975.25.
9
Pancreatic Cysts in Autosomal Dominant Polycystic Kidney Disease: Prevalence and Association with PKD2 Gene Mutations.常染色体显性多囊肾病中的胰腺囊肿:患病率及与PKD2基因突变的关联
Radiology. 2016 Sep;280(3):762-70. doi: 10.1148/radiol.2016151650. Epub 2016 Apr 5.
10
Bilineal inheritance of pathogenic PKD1 and PKD2 variants in a Czech family with autosomal dominant polycystic kidney disease - a case report.捷克一个常染色体显性多囊肾病家族中致病PKD1和PKD2变异的双系遗传——病例报告
BMC Nephrol. 2018 Jul 4;19(1):163. doi: 10.1186/s12882-018-0978-2.

引用本文的文献

1
Hypertension increases PPV for polycystic kidney disease in PKD1 and PKD2 variant carriers.高血压会增加携带PKD1和PKD2基因变异的多囊肾病患者的脉压变异率。
HGG Adv. 2025 Jul 10;6(3):100444. doi: 10.1016/j.xhgg.2025.100444. Epub 2025 Apr 23.
2
Autosomal dominant polycystic kidney disease: an overview of recent genetic and clinical advances.常染色体显性多囊肾病:近期遗传学和临床进展概述
Ren Fail. 2025 Dec;47(1):2492374. doi: 10.1080/0886022X.2025.2492374. Epub 2025 Apr 23.
3
Metformin Use and Clinical Outcomes in Autosomal Dominant Polycystic Kidney Disease: A Nationwide Cohort Study.

本文引用的文献

1
Evolving role of genetic testing for the clinical management of autosomal dominant polycystic kidney disease.遗传性检测在常染色体显性遗传性多囊肾病临床管理中的作用演变。
Nephrol Dial Transplant. 2019 Sep 1;34(9):1453-1460. doi: 10.1093/ndt/gfy261.
2
Prevalence Estimates of Polycystic Kidney and Liver Disease by Population Sequencing.人群测序估算多囊肾病和多囊肝病的患病率。
J Am Soc Nephrol. 2018 Oct;29(10):2593-2600. doi: 10.1681/ASN.2018050493. Epub 2018 Aug 22.
3
Monoallelic Mutations to DNAJB11 Cause Atypical Autosomal-Dominant Polycystic Kidney Disease.
二甲双胍在常染色体显性多囊肾病中的应用及临床结局:一项全国性队列研究
Biomedicines. 2025 Mar 5;13(3):635. doi: 10.3390/biomedicines13030635.
4
Genetic and protein structure prediction analyses identify a rare pathogenic PKD1 variant causing autosomal dominant polycystic kidney disease.基因和蛋白质结构预测分析鉴定出一种导致常染色体显性多囊肾病的罕见致病性PKD1变异。
CEN Case Rep. 2025 Mar 14. doi: 10.1007/s13730-025-00985-4.
5
Biomarkers of Kidney Disease Progression in ADPKD.常染色体显性多囊肾病中肾病进展的生物标志物
Kidney Int Rep. 2024 Jul 14;9(10):2860-2882. doi: 10.1016/j.ekir.2024.07.012. eCollection 2024 Oct.
6
Trigger Warning: How Modern Diet, Lifestyle, and Environment Pull the Trigger on Autosomal Dominant Polycystic Kidney Disease Progression.触发警告:现代饮食、生活方式和环境如何引发常染色体显性遗传性多囊肾病的进展。
Nutrients. 2024 Sep 27;16(19):3281. doi: 10.3390/nu16193281.
7
Data driven approach to characterize rapid decline in autosomal dominant polycystic kidney disease.数据驱动方法分析常染色体显性遗传性多囊肾病的快速进展。
PLoS One. 2024 Jun 5;19(6):e0298484. doi: 10.1371/journal.pone.0298484. eCollection 2024.
8
How Does ADPKD Severity Differ Between Family Members?常染色体显性多囊肾病在家庭成员之间的严重程度如何不同?
Kidney Int Rep. 2024 Feb 5;9(5):1198-1209. doi: 10.1016/j.ekir.2024.01.053. eCollection 2024 May.
9
Clinical Utility of Genetic Testing with Geographical Locations in ADPKD: Describing New Variants.常染色体显性多囊肾病中基因检测结合地理位置的临床应用:描述新变异体
J Clin Med. 2024 Mar 18;13(6):1751. doi: 10.3390/jcm13061751.
10
Familial Variability of Disease Severity in Adult Patients With ADPKD.成人常染色体显性多囊肾病患者疾病严重程度的家族变异性
Kidney Int Rep. 2023 Dec 12;9(3):649-660. doi: 10.1016/j.ekir.2023.12.002. eCollection 2024 Mar.
DNAJB11 的单等位基因突变导致非典型常染色体显性多囊肾病。
Am J Hum Genet. 2018 May 3;102(5):832-844. doi: 10.1016/j.ajhg.2018.03.013. Epub 2018 Apr 26.
4
The Value of Genetic Testing in Polycystic Kidney Diseases Illustrated by a Family With PKD2 and COL4A1 Mutations.遗传性多囊肾病中基因检测的价值:一个 PKD2 和 COL4A1 基因突变家系的实例分析。
Am J Kidney Dis. 2018 Aug;72(2):302-308. doi: 10.1053/j.ajkd.2017.11.015. Epub 2018 Feb 1.
5
Baseline total kidney volume and the rate of kidney growth are associated with chronic kidney disease progression in Autosomal Dominant Polycystic Kidney Disease.在常染色体显性多囊肾病中,基线总肾体积和肾脏生长速度与慢性肾脏病进展相关。
Kidney Int. 2018 Mar;93(3):691-699. doi: 10.1016/j.kint.2017.09.027. Epub 2017 Dec 28.
6
Genetic architecture: the shape of the genetic contribution to human traits and disease.遗传结构:遗传对人类特征和疾病的贡献方式。
Nat Rev Genet. 2018 Feb;19(2):110-124. doi: 10.1038/nrg.2017.101. Epub 2017 Dec 11.
7
A Drug Development Tool for Trial Enrichment in Patients With Autosomal Dominant Polycystic Kidney Disease.一种用于常染色体显性多囊肾病患者试验富集的药物开发工具。
Kidney Int Rep. 2017 Feb 21;2(3):451-460. doi: 10.1016/j.ekir.2017.02.011. eCollection 2017 May.
8
Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease.托伐普坦治疗晚期常染色体显性遗传性多囊肾病。
N Engl J Med. 2017 Nov 16;377(20):1930-1942. doi: 10.1056/NEJMoa1710030. Epub 2017 Nov 4.
9
New treatment paradigms for ADPKD: moving towards precision medicine.多囊肾病的新治疗模式:迈向精准医学。
Nat Rev Nephrol. 2017 Dec;13(12):750-768. doi: 10.1038/nrneph.2017.127. Epub 2017 Oct 9.
10
Polycystic Kidney Disease without an Apparent Family History.无明显家族史的多囊肾病
J Am Soc Nephrol. 2017 Sep;28(9):2768-2776. doi: 10.1681/ASN.2016090938. Epub 2017 May 18.